Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober^*, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, Carle Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Kundu, Chitra Sekaran, Misti Linaberry, Subhashis Banerjee, Kim A. Papp

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Entzündungsmedizin

Yale University
David Geffen School of Medicine at UCLA
Mount Sinai School of Medicine
University of Wisconsin-Madison
University of Melbourne
Oregon Dermatology & Research Center
Toulouse University School of Medicine
Psoriasis Treatment Center of New Jersey
Bristol-Myers Squibb
Probity Medical Research

239 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

sortieren
Gewichtung
Alphabetisch

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Fingerprint

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science